Skip to content

TriHealth is notifying individuals whose information was involved in a recent third-party data security incident. Click here for more information. Click here for additional information on the recent Datavant Breach.

June 18, 2018

Bethesda North and Good Samaritan Hospitals First in Cincinnati to Offer Innovative TCAR Procedure to Treat Carotid Artery Disease

Share

June 18, 2018

TriHealth’s Bethesda North and Good Samaritan Hospitals are the first hospitals in the city of Cincinnati and two of only four hospitals in the entire state of Ohio treating carotid artery disease and preventing future strokes using a new procedure called TransCarotid Artery Revascularization (TCAR). TCAR (tee-kahr) is a clinically proven, minimally invasive and safe approach for high surgical risk patients who need carotid artery treatment.

“TCAR is an important new option in the fight against stroke, and is particularly suited for the large portion of patients we see who are at higher risk of complications from carotid surgery due to age, anatomy, or other medical conditions,” said Dr. Brian Kuhn, Vascular Surgeon at TriHealth. “Because of its low stroke risk and faster patient recovery, I believe TCAR represents the future of carotid repair.”

Carotid artery disease is a form of atherosclerosis, or a build-up of plaque, in the two main arteries in the neck that supply oxygen-rich blood to the brain. If left untreated, carotid artery disease can often lead to stroke; it is estimated to be the source of stroke in up to a third of cases, with 400,000 new diagnoses of the disease made every year in the U.S. alone.

TCAR is unique in that blood flow is temporarily reversed during the procedure so that any small bits of plaque that may break off are diverted away from the brain, preventing a stroke from happening. A stent is then placed inside the artery to stabilize the plaque, minimizing the risk of a future stroke.

“It seemed so easy compared to the other surgeries I’ve had, and the recovery was much faster,” said Peter Joseph, who was considered too risky for traditional surgery. “I was out of the hospital the day after the procedure with a much smaller scar than I expected.”

Prior to TCAR, the main treatment option for severe carotid artery disease was an open surgical procedure called carotid endarterectomy (CEA). CEA removes plaque from inside the carotid artery to restore normal blood flow to the brain, but the large incision leaves a visible scar the length of the neck and carries risks of surgical complications including bleeding, infection, heart attack and cranial nerve injuries that can cause issues with swallowing, speaking and sensation in the face.

The TCAR procedure was developed by Sunnyvale, California-based Silk Road Medical, Inc. and includes the ENROUTE® Transcarotid Neuroprotection (NPS) and Stent System–the first devices designed and FDA-approved specifically for TCAR. Over 3,000 TCAR procedures have been performed worldwide through clinical trial and commercial use. TCAR has been studied extensively, and the clinical data have been excellent. Additional information about TCAR is available at http://silkroadmed.com/disease-and-treatment-options/.

 

Coverage of TCAR:

WCPO: 

Local 12:

Preventing stroke: TCAR procedure treats carotid artery disease